Merck & Co. is investing in new products and research to sustain growth as its key cancer drug, KEYTRUDA, nears loss of market exclusivity. Despite a recent 1.91% daily stock drop to $144.71, Merck's shares gained nearly 11% over the past month, outperforming the broader market. Analyst Luisa Hector set a price target of $137, below the current price, signaling cautious investor outlook. Investors await Merck's upcoming financial report, with earnings expected at $2.27 per share and revenue forecasted to rise 1.94% to $17.61 billion.
Investors in the Schwab U.S. Dividend Equity ETF (SCHD) who reinvested dividends over the past decade earned about $1.03 million from a $300,000 investment, trailing the S&P 500 index's $1.25 million by over $216,000. Despite a low expense ratio of 0...
Moderna's stock surged 8% in a single day despite no new announcements, regulatory decisions, or clinical trial updates to justify the move. This rally comes after a 143% gain over the past month, largely driven by positive results from its personali...
